Efusi Pleura

01Pathophysiology

The pleural space normally contains approximately 5 to 15 mL of fluid that acts as a lubricant between the visceral and parietal pleura. This fluid is maintained by a balance between hydrostatic pressure (pushing fluid into the space), oncotic pressure (pulling fluid back into the vasculature), and lymphatic drainage (removing excess fluid and protein from the pleural space). A pleural effusion develops when any of these mechanisms is disrupted, leading to net fluid accumulation.

Transudative effusions occur when systemic factors alter the hydrostatic-oncotic balance without directly affecting the pleural membrane. In congestive heart failure, elevated pulmonary venous pressure increases the hydrostatic gradient, pushing fluid into the pleural space. In cirrhosis, ascitic fluid migrates through diaphragmatic defects (called hepatic hydrothorax), and the low serum albumin further reduces plasma oncotic pressure. In nephrotic syndrome, the primary driver is hypoalbuminemia reducing the oncotic gradient. The pleura itself is healthy in all these cases, which is why the fluid is protein-poor and cell-poor.

Exudative effusions arise from local pathology affecting the pleura directly. In pneumonia, bacterial infection triggers an inflammatory cascade that increases capillary permeability, allowing protein-rich fluid and inflammatory cells to leak into the pleural space (parapneumonic effusion). If bacteria invade the pleural space itself, the result is empyema, characterized by frank pus, very low pH, and very low glucose. In malignancy, tumor cells can directly implant on the pleural surface, obstruct lymphatic drainage, or both, leading to protein-rich, often bloody fluid. In tuberculosis, a delayed-type hypersensitivity reaction causes granulomatous inflammation of the pleura with a lymphocyte-predominant exudate.

The clinical symptoms are a direct consequence of the fluid's mechanical effects. As fluid accumulates, it compresses the underlying lung parenchyma, reducing functional residual capacity and causing dyspnea. Pleuritic chest pain occurs when the inflamed parietal pleura (which is innervated, unlike the visceral pleura) is stretched or irritated. Large effusions shift the mediastinum toward the contralateral side, potentially compressing the opposite lung and causing tracheal deviation.

02Classification and Clinical Manifestation

Light's Criteria

An effusion is classified as exudative if it meets any one of the following criteria. If none are met, it is transudative.

Common Causes by Category

Clinical Manifestation by Effusion Size

03Diagnostic Workup

The workup begins with an upright posteroanterior (PA) chest X-ray, which is the best initial test. The classic finding is blunting of the costophrenic angle with a meniscus-shaped opacity that curves upward laterally. A completely opacified hemithorax with contralateral mediastinal shift indicates a large effusion, while ipsilateral shift (or no shift) with complete opacification should raise suspicion for an obstructive process such as a central bronchial mass causing atelectasis with concurrent effusion.

If there is uncertainty about whether the opacity represents fluid versus consolidation or a mass, a lateral decubitus film (patient lying on the affected side) is the next step. Free-flowing fluid will layer along the dependent chest wall. If the layering measures greater than 10 mm, the effusion is large enough to safely perform a diagnostic thoracentesis. If the fluid does not layer, it is either loculated or not truly an effusion.

Point-of-care ultrasound has increasingly replaced the lateral decubitus film in clinical practice and is considered the most sensitive bedside tool for detecting pleural effusions. It can detect volumes as small as 20 mL, identify septations or loculations, and guide safe needle placement for thoracentesis. Exam questions may test the utility of ultrasound guidance to reduce complications such as pneumothorax.

Thoracentesis is the most important diagnostic step and should be performed on virtually all new, clinically significant effusions unless the clinical picture strongly suggests a transudative cause that will respond to treatment (e.g., bilateral effusions in a patient with known decompensated heart failure). The fluid is sent for protein, LDH, glucose, pH, cell count with differential, Gram stain, culture, and cytology. Additional studies such as amylase (pancreatitis, esophageal rupture), triglycerides (chylothorax), and adenosine deaminase/ADA (tuberculosis) are ordered based on clinical suspicion.

Light's criteria are then applied to classify the effusion. One important caveat: patients with heart failure on chronic diuretic therapy may have a transudative effusion that is misclassified as exudative because diuresis concentrates the pleural fluid protein and LDH. In this scenario, the serum-to-pleural-fluid albumin gradient should be calculated. If the gradient is greater than 1.2 g/dL, the effusion is likely transudative despite meeting Light's exudative criteria.

For exudative effusions, the pleural fluid pH and glucose are critical for decision-making. A parapneumonic effusion with a pH < 7.2, glucose < 60 mg/dL, positive Gram stain, or frank pus is classified as a complicated parapneumonic effusion or empyema and requires chest tube drainage rather than antibiotics alone.

If cytology is negative after two thoracenteses in a patient with a high suspicion for malignancy, the next step is thoracoscopy (medical or video-assisted thoracoscopic surgery/VATS) with pleural biopsy. This is the gold standard for confirming malignant pleural disease and mesothelioma. For suspected tuberculous pleuritis, pleural biopsy showing caseating granulomas is the most accurate confirmatory test, though a markedly elevated pleural fluid ADA (> 40 U/L) in a lymphocyte-predominant exudate is highly suggestive in endemic areas.

04Management and Treatment

The foundational principle is to treat the underlying cause. A transudative effusion from heart failure does not require thoracentesis unless the patient has refractory dyspnea despite adequate diuresis. The initial management is aggressive volume management with intravenous furosemide (starting at 40 mg IV, doubling the dose if urine output is inadequate). For hepatic hydrothorax, the target is the ascites: sodium restriction (< 2 g/day) and dual diuretic therapy with spironolactone (100 mg/day) and furosemide (40 mg/day), titrated in a 100:40 ratio. TIPS (transjugular intrahepatic portosystemic shunt) is considered for refractory cases.

For parapneumonic effusions, the distinction between uncomplicated and complicated determines management. An uncomplicated parapneumonic effusion (small, free-flowing, pH > 7.2, glucose > 60, negative cultures) resolves with antibiotics directed at the underlying pneumonia and does not need drainage. A complicated parapneumonic effusion (pH < 7.2, glucose < 60, positive Gram stain or culture, or loculated fluid) requires prompt chest tube insertion in addition to antibiotics. Failure to drain a complicated effusion leads to organization, fibrous peel formation, and potentially the need for decortication surgery.

Empyema (frank pus or positive culture from the pleural space) always requires drainage plus antibiotics. If the effusion is loculated and draining poorly, intrapleural fibrinolytic therapy with tissue plasminogen activator (tPA, 10 mg) combined with deoxyribonuclease (DNase, 5 mg) given intrapleurally twice daily for 3 days has been shown to improve drainage and reduce the need for surgery. If this fails, VATS decortication is the next step.

For malignant pleural effusions, the goal is palliation. Initial management is a large-volume therapeutic thoracentesis (up to 1000 to 1500 mL, stopping if the patient develops chest tightness, cough, or if pleural pressure drops significantly). If the effusion recurs rapidly (which is common in malignancy), chemical pleurodesis with talc slurry via chest tube or talc poudrage via thoracoscopy is performed to obliterate the pleural space and prevent reaccumulation. For patients with trapped lung (the lung cannot re-expand to appose the chest wall), pleurodesis will not work, and an indwelling pleural catheter (IPC) is the preferred approach, allowing the patient to drain fluid at home.

For chylothorax, initial management is conservative: nil per os (NPO) or a diet restricted to medium-chain triglycerides (MCT). MCTs are absorbed directly into the portal venous system, bypassing the thoracic duct entirely and reducing chyle production. If conservative management fails after 2 weeks, or if output exceeds 1.5 L/day, thoracic duct ligation (surgical or interventional) is indicated.

05Differential Diagnosis and Distractors

06Traps and High-Yield Pearls

The single most common trap with pleural effusion questions is failing to apply Light's criteria correctly. Students often memorize the thresholds but forget that meeting any one of the three criteria classifies the effusion as exudative. The exam will present a case where only one parameter barely crosses the threshold, and the correct answer hinges on recognizing that a single positive criterion is sufficient.

The second major trap involves the diuretic pitfall. A patient with known heart failure on chronic furosemide therapy undergoes thoracentesis, and the fluid meets Light's criteria for an exudate. The unwary student selects an exudative workup. The correct approach is to calculate the serum-to-pleural-fluid albumin gradient. If it exceeds 1.2 g/dL, the effusion is a "pseudo-exudate," and the patient should be managed as transudative (continued diuresis, not a biopsy or CT-guided drainage).

Another frequently tested concept is the decision to place a chest tube in parapneumonic effusions. The exam will present a patient with pneumonia and a new effusion, then ask for the next best step. The answer depends entirely on the thoracentesis results: pH < 7.2 or glucose < 60 mg/dL mandates drainage, even if the fluid looks clear. Students who skip ahead to "antibiotics alone" without checking the pleural fluid pH will miss this.

Finally, remember that pulmonary embolism can cause either a transudative or an exudative effusion, making it a diagnosis that does not fit neatly into the Light's criteria framework. When a vignette describes a small, unilateral, bloody effusion in a patient with risk factors for DVT (recent surgery, immobilization, oral contraceptive use), the intended diagnosis is PE, and the next best step is CT pulmonary angiography, not repeated thoracentesis.

The core competency being tested across all pleural effusion questions is the ability to systematically classify the effusion, interpret thoracentesis results in clinical context, and match the management to the category and severity of the effusion rather than reflexively treating all effusions the same way.